Compare iShares MBS ETF (MBB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Novartis AG — how do they compare? iShares MBS ETF trades at $89.7 (market cap $35.45B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 7.7× iShares MBS ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Novartis AG for 82 Days on average.
| MBB | NVS | |
|---|---|---|
Market Cap | $35.45B | $274.00B |
Volume | 4,982,386 | 1,852,137 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $168.62 |
52-Week Low | $89.09 | $121.80 |
Typical Hold Time | 96 Days | 82 Days |
Enterprise Value | — | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.22, down 0.16% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The ETF faces headwinds from rising intermediate-term rates and inflation, as noted in recent analysis, while short interest has surged significantly. Recent corporate actions include scheduled dividend payments, but key financial ratios are not available in the provided data.
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. Investment opportunities exist for income-focused investors attracted to its dividend yield, but risks include further rate hikes and prepayment volatility. Investors should weigh the ETF's role in a diversified fixed income portfolio against potential duration-related losses.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
